We are focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey.
Our Approach
With an obesity-first focus, our pipeline is specifically designed to address critical needs in the current therapeutic landscape.
Our Pipeline
Kailera’s four clinical-stage product candidates leverage multiple GLP-1- based mechanisms of action and routes of administration.
Our Clinical Trials
Learn about Kailera’s ongoing clinical trials for people living with obesity.
Recent Press Releases
January 12, 2026
Kailera Therapeutics Announces First Participants Randomized in KaiNETIC Global Phase 3 Clinical Program of GLP-1/GIP Receptor Dual Agonist Ribupatide (KAI-9531)
January 5, 2026
Kailera Therapeutics Appoints Doug Pagán as Chief Financial Officer
December 23, 2025